NCT03036306View on ClinicalTrials.gov

Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 2, 2017

Study Completion Date

October 2, 2017

Conditions

Scarring

Interventions

DRUG

SCX-001

Nefopam cream formulation

OTHER

Placebo

Cream formulation without Nefopam

Trial Locations (1)

T6G 2B7

University of Alberta Hospital, Edmonton

All Listed Sponsors

lead

ScarX Corp

INDUSTRY

NCT03036306 - Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions | Biotech Hunter | Biotech Hunter